Announcements Trials
Browse Landscape

Phase

Phase 2 73Phase 1 45Phase 1/2 33Phase 3 27Phase 2/3 4Phase NA 3Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 9Biopsy 8Nivolumab 7Radiotherapy 6Specimen Handling 5Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Temozolomide 3Rituximab 3Paclitaxel 3Leukapheresis 3Dexamethasone 3Aspirin 3perflutren 2alovudine 2Vaccines 2Tirzepatide 2Surgical Procedures, Operative 2Positron-Emission Tomography 2Phantoms, Imaging 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Irinotecan 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × venetoclax × 90 days × Clear all
NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡